[Ip-health] KEI Policy Brief: Non-Voluntary use of HCV patents in the United States

Jamie Love james.love at keionline.org
Fri Jul 18 05:47:14 PDT 2014


Source URL: http://keionline.org/node/2058

KEI Policy Brief: Non-Voluntary use of HCV patents in the United States

July 18, 2014

Attached is policy briefing note that sets out possible mechanisms to
overcome the exclusive rights of patents for drugs to treat the Hepatitis C
Virus (HCV), in the United States. Each approach involves leadership from
different actors. Each has advantages and disadvantages, including legal
and practical risks. (Available here [1])

Table of Contents

1. The Federal Government use of HCV patents, without permission from right
holder
2. State Government Use of HCV patents, without permission from right holder
3. Private Infringement of HCV patents, without permission from right holder
4. Risks Posed by Trade Agreements
5. Patent Buyout
6. Patent Pool
7. Prize Fund
8. Customs Issues
9. Concluding Comments

The suggested citation: James Love, Non­voluntary use of patents for drugs
to treat the Hepatitis C Virus in the United States: Mechanisms available
to the Federal Government, State Governments and Private Actors, KEI Policy
Brief 2014:1. July 18, 2014


[1]
http://keionline.org/sites/default/files/Non-voluntary_use_HCV_patents_USA.pdf

-- 
James Love.  Knowledge Ecology International
http://www.keionline.org, KEI DC tel: +1.202.332.2670, US Mobile:
+1.202.361.3040, Geneva Mobile: +41.76.413.6584,   twitter.com/jamie_love



More information about the Ip-health mailing list